WallStSmart

Apollo Global Management LLC Class A (APO)vsBlackRock Health Sciences Trust II (BMEZ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

APO leads profitability with a 11.0% profit margin vs 0.0%. BMEZ trades at a lower P/E of 5.4x. APO earns a higher WallStSmart Score of 63/100 (C+).

APO

Buy

63

out of 100

Grade: C+

Growth: 7.3Profit: 6.0Value: 7.3Quality: 2.8
Piotroski: 1/9Altman Z: 0.07

BMEZ

Avoid

30

out of 100

Grade: F

Growth: 3.3Profit: 4.0Value: 7.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

APOSignificantly Overvalued (-237.0%)

Margin of Safety

-237.0%

Fair Value

$37.67

Current Price

$109.80

$72.13 premium

UndervaluedFair: $37.67Overvalued
BMEZUndervalued (+12.7%)

Margin of Safety

+12.7%

Fair Value

$17.27

Current Price

$14.00

$3.27 discount

UndervaluedFair: $17.27Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APO4 strengths · Avg: 8.8/10
Revenue GrowthGrowth
87.7%10/10

Revenue surging 87.7% year-over-year

Market CapQuality
$64.57B9/10

Large-cap with strong market position

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.82B8/10

Generating 2.8B in free cash flow

BMEZ1 strengths · Avg: 10.0/10
P/E RatioValuation
5.4x10/10

Attractively priced relative to earnings

Areas to Watch

APO3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

EPS GrowthGrowth
-57.3%2/10

Earnings declined 57.3%

Altman Z-ScoreHealth
0.072/10

Distress zone — elevated risk

BMEZ4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$860.02M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : APO

The strongest argument for APO centers on Revenue Growth, Market Cap, Price/Book. Revenue growth of 87.7% demonstrates continued momentum. PEG of 1.21 suggests the stock is reasonably priced for its growth.

Bull Case : BMEZ

The strongest argument for BMEZ centers on P/E Ratio.

Bear Case : APO

The primary concerns for APO are Piotroski F-Score, EPS Growth, Altman Z-Score.

Bear Case : BMEZ

The primary concerns for BMEZ are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

APO profiles as a growth stock while BMEZ is a value play — different risk/reward profiles.

APO is growing revenue faster at 87.7% — sustainability is the question.

APO generates stronger free cash flow (2.8B), providing more financial flexibility.

Monitor ASSET MANAGEMENT industry trends, competitive dynamics, and regulatory changes.

Bottom Line

APO scores higher overall (63/100 vs 30/100) and 87.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Apollo Global Management LLC Class A

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

Apollo Global Management LLC Class A (APO) is a leading global alternative investment firm, specializing in private equity, credit, and real estate across a wide array of sectors such as healthcare, financial services, and technology. The firm employs a disciplined investment strategy that leverages deep industry expertise and operational insight to enhance portfolio value. With a strong commitment to long-term growth, Apollo seeks to identify and capitalize on strategic investment opportunities in both developed and emerging markets. As a publicly traded entity, it aims to deliver attractive risk-adjusted returns to investors through its substantial capital resources and strategic initiatives.

BlackRock Health Sciences Trust II

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

BlackRock Health Sciences Trust II (BMEZ) is a closed-end fund actively managed to deliver high total returns through a diversified portfolio primarily focused on the health sciences sector, encompassing pharmaceuticals, biotechnology, and medical devices. Backed by the expertise of BlackRock, a leading global investment manager, BMEZ capitalizes on the significant growth potential and innovation trends driven by demographic changes and increased healthcare expenditures. With a disciplined investment approach, this fund represents an appealing opportunity for institutional investors seeking to capitalize on the dynamic and evolving landscape of health sciences, thereby enhancing their overall investment strategies.

Want to dig deeper into these stocks?